Remote & Decentralized Clinical Trials in 2026: What the FDA Actually Says

Remote clinical research is real, it is regulated, and it is growing, but it is far more specific and constrained than the phrase suggests. The question is not whether clinical trials can happen remotely. The FDA settled that with its final guidance in September 2024. The question is which activities can go remote, under what conditions, with what documentation, and who remains accountable when they do. For Clinical Research Coordinators, understanding the actual regulatory framework, not just the concept — is what separates a working understanding of decentralized trials from a vague impression that things are becoming more flexible.

This guide draws entirely from official FDA guidance documents, peer-reviewed literature via NIH's National Library of Medicine, and the current ICH GCP E6(R3) framework. No claims about the state of remote clinical research are made without a verified official source.

What Is a Decentralized Clinical Trial?

The FDA defines a decentralized clinical trial (DCT) as a clinical trial that includes decentralized elements, where some or all trial-related activities occur at locations other than traditional clinical trial sites. This definition, established in the FDA's September 2024 final guidance on Conducting Clinical Trials With Decentralized Elements, is precise: a DCT is not necessarily a fully remote trial. It is a trial that incorporates decentralized elements, some activities may occur remotely while others remain site-based.

Decentralized elements can include telehealth visits with trial personnel, in-home visits with remote trial personnel or local healthcare providers, and the use of digital health technologies (DHTs) to collect data from participants at their location. The extent of decentralization depends entirely on what the protocol requires, what the sponsor has designed, and what the FDA has accepted as appropriate for that specific trial.

Critically, as the FDA's press announcement accompanying the guidance makes clear: the regulatory requirements for DCTs are the same as for traditional site-based clinical trials. Decentralization changes where activities happen, not what standards govern them.

FDA's Regulatory Framework: The Final September 2024 Guidance

The September 2024 final guidance — Conducting Clinical Trials With Decentralized Elements — is the current authoritative FDA statement on DCTs. It supersedes the May 2023 draft guidance and reflects FDA's formalized thinking after public comment. The guidance is intended for sponsors, investigators, and other interested parties and covers the implementation of decentralized elements across drugs, biological products, and devices.

The guidance was issued as part of FDA's response to two legislative mandates: Sections 3606 and 3607 of the Food and Drug Omnibus Reform Act of 2022 (FDORA), which directed FDA to publish guidance on the modernization of clinical trials through decentralized elements and digital health technologies. It also builds on COVID-19 pandemic experience, when the FDA issued 2020 guidance allowing investigators to decentralize certain activities in response to site closures and travel restrictions. The FDA's Oncology Center of Excellence specifically identified COVID-19 as a proof of concept for several DCT modifications, including electronic informed consent, virtual clinic visits, home delivery of investigational product, and local laboratory or imaging assessments.

The guidance identifies several reasons why DCTs may benefit clinical research: they can enhance convenience for trial participants, reduce the burden on caregivers, expand access to more diverse patient populations, improve trial efficiencies, and facilitate research on rare diseases and diseases affecting populations with limited mobility. These are not aspirational claims — they are the FDA's stated rationale for actively supporting DCT adoption.

What Can Go Remote Under FDA's Framework

The final guidance identifies a range of activities that can be conducted remotely or at locations other than the traditional clinical trial site, subject to protocol design, sponsor implementation, and appropriate regulatory documentation:

• Telehealth visits with trial personnel. Follow-up assessments, symptom reviews, patient-reported outcome collection, and monitoring contacts can be conducted via telehealth when the protocol supports it and appropriate consent and privacy protections are in place.
• In-home visits with remote trial personnel. A trial staff member may conduct a home visit to perform assessments that cannot be done purely via telehealth but that do not require the infrastructure of a traditional site.
• Local healthcare provider (HCP) visits. The guidance explicitly permits investigators to work with enrolled participants to identify local HCPs, near the participant's home rather than the research site, to conduct certain protocol-required assessments. The investigator remains responsible for ensuring these delegated activities are conducted according to the investigational plan and applicable regulations.
• Remote data collection via digital health technologies. Wearables, mobile applications, electronic patient-reported outcomes, and other DHTs can collect trial data continuously or at specified intervals without requiring a site visit. See the DHT section below for the applicable framework.
• Electronic informed consent. The guidance addresses eConsent in the DCT context, including IRB oversight requirements for the eConsent process. Electronic consent must still meet all requirements of 21 CFR Part 50, the medium changes, not the substantive requirements.
• Local laboratory and imaging assessments. Rather than requiring participants to travel to the research site for blood draws or imaging, these can be conducted at local facilities, with appropriate chain-of-custody and data transfer procedures in place.

What Stays On-Site: The Limits of Decentralization

The FDA guidance is explicit that not all activities can be decentralized. The extent of decentralization in any given trial depends on the types of assessments and procedures needed to collect endpoints and monitor safety. Whether an activity can move off-site is a protocol-specific determination, not a blanket authorization.

Activities that generally cannot be decentralized include complex medical procedures that require on-site infrastructure and immediate medical oversight; initial eligibility assessments that require physical examination or specialized equipment; infusions or injections that require trained staff and emergency response capability on-site; and safety monitoring that requires immediate access to resuscitation equipment or specialist consultation. The guidance notes that additional training, coordination, and standard operating procedures are required for any decentralized elements to ensure consistent implementation — decentralization does not reduce procedural complexity, it relocates it.

The guidance also addresses the practical limits of DHTs and telehealth for endpoint collection. Some clinical endpoints — objective measures that require specific calibrated instruments, direct physical assessment by a qualified clinician, or laboratory analysis in a certified facility — cannot be validly collected remotely. The sponsor must justify, in the protocol and IND, that the remote collection method produces data of equivalent quality to the traditional on-site method.

Digital Health Technologies: The Enabling Infrastructure

The FDA published a companion final guidance in December 2023 specifically governing the use of digital health technologies in clinical investigations: Digital Health Technologies for Remote Data Acquisition in Clinical Investigations. This guidance provides recommendations on selecting appropriate DHTs, validating them for use in a specific trial, and using DHT-derived data as trial endpoints.

DHTs for remote data acquisition can include wearable sensors that collect physiological measurements such as heart rate, activity level, or glucose levels; mobile applications that capture patient-reported outcomes; electronic diaries; and connected devices that transmit measurements directly to clinical data management systems. The FDA DHT program for drug development outlines FDA's commitment to supporting DHT use and has established a DHT Steering Committee with senior staff from CDER, CBER, and CDRH to coordinate policy development.

For CRCs working on DCTs that incorporate DHTs, several practical implications follow from the guidance. Sponsors must verify and validate each DHT for use in the specific investigation — validation for one trial does not automatically carry over to another, even if the same device is used. Data originator identification must be documented: for patient-reported outcomes, the participant is the data originator; for automatically transmitting devices, the device itself is the data originator. Chain of data transmission from DHT to the durable electronic data repository must be documented and auditable. All of this generates source documentation obligations that CRCs need to understand and manage.

Investigational Product Delivery to the Home

One of the most operationally significant features of DCTs is the possibility of delivering investigational product (IP) directly to a participant's home rather than requiring site visits for dispensing. The FDA's DCT guidance addresses this directly, covering the packaging, labeling, and shipping requirements for IP in a DCT context.

Home delivery of IP is not unrestricted. It requires that the IP be appropriate for home use, meaning it can be safely stored and administered by or to the participant without clinical infrastructure on-site. The sponsor must ensure appropriate labeling that accounts for home storage conditions; establish a system for temperature monitoring during shipment where the IP requires controlled storage; document chain of custody from site or pharmacy to participant; and establish procedures for retrieving unused, expired, or returned IP from participants' homes.

For CRCs, home IP delivery does not eliminate drug accountability obligations — it changes how they are fulfilled. Every unit shipped to a participant's home must still be tracked from receipt to final disposition. The IP accountability record must document shipment date and tracking information, delivery confirmation, the participant's acknowledgment of receipt, any reported storage conditions, and the disposition of any returned product. The Drug Accountability Calculator on this site can help you maintain the running reconciliation that home delivery requires.

Electronic Informed Consent in DCTs

Electronic informed consent (eConsent) is a key enabling tool for DCTs — it allows sponsors to initiate the consent process without requiring participants to travel to a site before their first study activity. The FDA's DCT guidance addresses eConsent in detail, incorporating the requirements of the FDA's finalized August 2023 Informed Consent guidance into the DCT context.

Several requirements are unchanged regardless of whether consent is obtained electronically or in person. The eConsent process must still include all eight basic elements required by 21 CFR Part 50. The IRB must review and approve the eConsent process and all materials, the medium does not change the IRB's oversight responsibility. The participant must have a genuine opportunity to ask questions and have them answered before signing. The investigator or their qualified designee must be available to address questions during the eConsent process.

The FDA's guidance also notes that a purely oral consent process conducted by telephone is not sufficient — there must be a documented, durable record of consent. A photographed image of a signed paper consent form transmitted electronically can satisfy this requirement in circumstances where in-person or fully electronic consent is not feasible, provided it is accompanied by appropriate attestation regarding its authenticity.

Why DCTs Matter for Trial Diversity

One of the most substantive benefits the FDA identifies for DCTs is their potential to expand access to more diverse patient populations. This matters clinically, not just ethically. A peer-reviewed analysis published in PMC drawing on an FDA- and NIH-attended multi-stakeholder conference found that decentralization of sites and use of digital tools can directly enhance the accessibility of clinical research, and that this is a key pathway to improving diversity in trial enrollment.

The traditional site-based model has created structural barriers to diverse enrollment: participants must live within reasonable travel distance of a research site, have transportation, be able to take time off work or arrange childcare for clinic visits, and navigate a system that has historically been located in academic medical centers concentrated in major urban areas. DCTs address all of these barriers directly. A participant who cannot travel three hours to a research hospital can participate in a trial with home visits, local lab draws, and telehealth follow-ups.

A National Academies report on representation in clinical trials specifically identifies decentralization as a structural solution to representation gaps — noting that overly restrictive study designs and activation of trials primarily at academically prominent sites has historically resulted in trial populations that do not reflect the diversity of the populations who will eventually use the approved treatment. For CRCs, this context reframes the work of implementing DCT elements: it is not administrative complexity for its own sake. It is access infrastructure for patients who have historically been excluded from the evidence generation process.

What Decentralized Trials Mean for CRCs in Practice

The growth of DCTs does not make the CRC role obsolete — it expands and reshapes it. Sites that adopt decentralized elements need coordinators who can manage a more distributed operational model: tracking IP that has been shipped to participant homes, coordinating with local HCPs who are conducting delegated assessments, monitoring DHT data streams for completeness and anomalies, and managing eConsent workflows that may begin before a participant ever sets foot on site.

Several practical implications follow for CRCs working on trials with decentralized elements:

• Delegation log entries must reflect the DCT structure. If a local HCP has been designated to perform protocol-required assessments, their role, qualifications, and the tasks delegated to them must be documented appropriately. The investigator's oversight of that delegation must also be documented.
• Source documentation expands to cover remote activities. A telehealth visit generates source documentation obligations just as an in-person visit does. The date, time, platform, personnel present, assessments conducted, and participant responses must all be documented contemporaneously and retained in the ISF or linked to it.
• IP accountability becomes more complex, not simpler. Home delivery chains require tracking at every step. A shipment that cannot be confirmed as received by the participant, stored correctly, and returned or disposed of appropriately is an accountability gap — exactly the kind that BIMO inspectors look for.
• Visit window calculations still apply. Decentralized visits conducted via telehealth or through local HCPs are still subject to the protocol's visit window requirements. A telehealth follow-up conducted outside its window is a protocol deviation regardless of where it occurred. The Visit Window Calculator applies to remote visits exactly as it does to in-person ones.
• DHT data requires source documentation review. When a wearable device generates endpoint data, the CRC needs to understand how that data flows from the device to the data repository, how it is attributed to the correct participant, and how discrepancies between DHT data and other source records are handled per the protocol's data management plan.

Remote clinical research is not a departure from the rigorous, participant-protective framework that governs all clinical trials. It is that same framework applied to a distributed operational model. CRCs who understand the regulatory basis for each DCT element, rather than just following a protocol checklist — are the ones who can identify when a process is drifting from what the guidance requires, and correct it before it becomes a finding.